Skip to main content
William Fearon, MD, Cardiology, Stanford, CA

William Fearon MD

Cardiology•Stanford, CA

Interventional Cardiology

Professor, Medicine - Cardiovascular Medicine, Stanford University

Join to View Full Profile

  • 300 Pasteur DrStanford, CA 94305

  • Phone+1 650-723-4000

Dr. Fearon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Fearon's Full ProfileAlready have an account?

Education & Training

  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityFellowship, Cardiovascular Disease, 1998 - 2001
  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1994 - 1997
  • Columbia University Vagelos College of Physicians and Surgeons
    Columbia University Vagelos College of Physicians and SurgeonsClass of 1994

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1995 - 2027
  • Cardiovascular Disease
    American Board of Internal Medicine Cardiovascular Disease
  • Interventional Cardiology
    American Board of Internal Medicine Interventional Cardiology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
  • Whos Who in Medicine and Healthcare Marquis Whos Who
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Association of Endothelin-1 with Accelerated Cardiac Allograft Vasculopathy and Late Mortality Following Heart Transplantation  
    Kiran Khush, Alan C Yeung, Hannah Valantine, William F Fearon, Journal of Cardiac Failure
  • Original Investigation High Coronary Shear Stress in Patients with Coronary Artery Disease Predicts Myocardial Infarction  
    Daniel Molloy, Hossein Hosseini, Habib Samady, Karthic Chandran, William F Fearon, Nikita Chand, ScienceDirect
  • Clinical Research Sex Differences in Adenosine-Free Coronary Pressure Indexes: A CONTRAST Substudy  
    Nils P Johnson, William F Fearon, Allen Jeremias, ScienceDirect
  • Join now to see all

Lectures

  • Pathophysiology of the Coronary Circulation in STEMI and NSTEMI 
    CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/26/2019
  • FFRangio Compared to FFR – Clinical Data and Subgroup MVD Analysis 
    CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/27/2019
  • Why Bother With 2 Stents? Just iFR or FFR the Ostial Circumflex 
    2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019

Authored Content

  • Fractional Flow Reserve and “Hard” EndpointsJune 2020
  • Fractional Flow Reserve and “Hard” EndpointsJune 2020
  • Focus on Coronary Physiology Assessment in Special Cohorts Editorial Comment Predicting Outcomes After Percutaneous Coronary Intervention Using Relative Change in Fractional Flow Reserve∗October 2018
  • Long-Term Prognostic Value of Invasive and Non-Invasive Measures Early After Heart TransplantationApril 2018
  • Long-Term Prognostic Value of Invasive and Non-Invasive Measures Early After Heart TransplantationApril 2018
  • Join now to see all

Press Mentions

  • CAVIAR: Early Initiation of PSCK9 plus Statin Therapy Safely Lowered LDL-C in Heart Transplant Patients; Did Not Reduce Coronary Artery Plaque Progression
    CAVIAR: Early Initiation of PSCK9 plus Statin Therapy Safely Lowered LDL-C in Heart Transplant Patients; Did Not Reduce Coronary Artery Plaque ProgressionNovember 10th, 2025
  • PCSK9 Inhibitor Combined with a Statin May Help Reduce LDL Cholesterol After Heart Transplant
    PCSK9 Inhibitor Combined with a Statin May Help Reduce LDL Cholesterol After Heart TransplantNovember 9th, 2025
  • Benefits Last 10 Years for Revascularization of Non-Culprit Vessels Following STEMI
    Benefits Last 10 Years for Revascularization of Non-Culprit Vessels Following STEMIJune 30th, 2025
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. William Fearon, Dr. William Fearon, MD, Dr. W Fearon